Novavax’s COVID-19 vaccine looks promising in early data NIH to test COVID-19 antibodies in hospitalized patients—starting with Eli Lilly’s India’s Zydus starts phase 2 COVID-19 vaccine trial after clearing safety test Versant debuts Matterhorn Biosciences with $30M to create better TCR treatments Novartis and a string of high profile backers fund next-gen Treg cell therapy startup GentiBio FDA turns back DBV Technologies’ peanut allergy patch, raising questions about its design Priming HER2 breast cancer with a vaccine to improve PD-1 inhibition We're looking for the most influential people in the fight against COVID-19 Featured Story | By Amirah Al Idrus A month after scoring $1.6 billion from the U.S. government, Novavax is posting the first human data from its COVID-19 vaccine. The early data, from the phase 1 part of a phase 1/2 study, show that two dose levels of the recombinant vaccine triggered an immune response similar to those in patients who had recovered from the disease. read more |
| |
|---|
|
Top Stories By Amirah Al Idrus As the quest for COVID-19 treatments continues, the National Institutes of Health (NIH) is starting an adaptive trial to test experimental antibody treatments for the disease. It’s starting with Eli Lilly and AbCellera’s candidate but could add more prospects as the trial goes on. read more By Nick Paul Taylor Zydus Cadila has completed a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 study. The Indian company said the DNA vaccine was well tolerated in the first stage of the adaptive phase 1/2 trial it initiated last month. read more By Amirah Al Idrus CAR-T therapies have transformed the treatment of some blood cancers but have run into hurdles in solid tumors. Other T-cell treatments can tackle some of those challenges, but their reach remains limited. Enter Matterhorn Biosciences, Versant Ventures’ latest startup, which is developing a tumor-agnostic T-cell approach. read more By Ben Adams OrbiMed, Novartis Venture Fund and RA Capital Management have joined forces to fund and help launch GentiBio. read more By Conor Hale The FDA has turned down DBV Technologies’ peanut allergy patch treatment for children, Viaskin Peanut, raising questions about the patch's design and performance. It's the latest turn in a long, winding path toward approval for the would-be allergy therapy. read more By Angus Liu Scientists at Duke University showed that priming the immune system with a vaccine targeting an oncogenic variant of HER2 helped existing checkpoint inhibiting drugs work better in mouse models of HER2-positive breast cancer. A phase 2 clinical trial testing the theory is already underway. read more By Staff Beating back the COVID-19 pandemic will take a massive effort by talented, dedicated people in biopharma and beyond. They're working now behind the scenes—scientists, researchers, manufacturing specialists, policy experts and many more—to deliver solutions. We aim to tell their stories in a special feature this fall. And we're looking for your nominations. read more Enrollment Showcase | Presented by: Biotility Taught by experienced professionals, Biotility’s online short courses provide the knowledge and practical skills valued by the bioscience industry. Enhance your career through coursework in one of our certificate pathways, including Document Management, Operations Management, and Quality Management. Learn more. |
| |
|---|
|
Resources Sponsored by: Acorn AI by Medidata, a Dassault Systèmes company Case Study: Oncology-focused pharmaceutical company strengthens product launch by identifying hundreds of high-value physicians with Acorn AI. Sponsored by: Paysign Download the whitepaper for a solution designed to connect manufacturers, pharmacists, and patients. In this special guide, you will learn not just about the law but about the portal platform designed to change the entire process for all. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Lonza Pharma & Biotech A novel spray-dried dispersion platform has been developed to faciliate high drug load applications Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. 18th Annual Discovery on Target Virtual September 16-18, 2020 Drug Development Boot Camp® 2020 November 18-19, 2020 | Register now! Pre-Boot Camp training ongoing now. | COVID19 provisions – training will be on-site as normal. | New – may be possible for some individuals to access the training virtually in real time. | 